2 sentences that change everything you THOUGHT you knew about trading

If you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfast... go to work... But if you say these two sentences to your broker... you could collect as much as $1,250 on Friday... no matter where you live, whether you're working or already retired. It all has to do with a unique stock market secret that's worked 97% of the time for the past 8 years running.

Ramesh Kumar Biography and Net Worth

Director of Ocugen

Dr. Ramesh Kumar Ph.D. serves as Independent Director of the Company. Dr. Kumar has served as a director of OpCo, our wholly owned subsidiary, since June 2019. He co-founded Onconova Therapeutics, Inc. in 1998 and served as its Chief Executive Officer and a member of its board from 1998 to February 2019 and as its President from 1998 to June 2018. Dr. Kumar transitioned to an Advisory role with Onconova in January 2019. He has held positions in R&D and management at Princeton University, Bristol-Myers Squibb, DNX (later Nextran, a subsidiary of Baxter) and Kimeragen (later Valigen), where he served as President of the Genomics and Transgenics Division. Dr. Kumar obtained an undergraduate and Master’s degree in Microbiology from Panjab University and received his Ph.D. in Molecular Biology from the University of Illinois, Chicago and trained at the National Cancer Institute. Our Board believes Dr. Kumar’s extensive senior executive and public company experience, and familiarity with the pharmaceutical industry qualify him to serve on our Board.

What is Ramesh Kumar's net worth?: The estimated net worth of Ramesh Kumar is at least $7,899.00 as of July 19th, 2021. Dr. Kumar owns 7,500 shares of Ocugen stock worth more than $7,899 as of November 8th. This net worth approximation does not reflect any other investments that Dr. Kumar may own. Learn More about Ramesh Kumar's net worth.
How do I contact Ramesh Kumar?: The corporate mailing address for Dr. Kumar and other Ocugen executives is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. Ocugen can also be reached via phone at (484) 328-4701 and via email at [email protected]. Learn More on Ramesh Kumar's contact information.
Has Ramesh Kumar been buying or selling shares of Ocugen?: Ramesh Kumar has not been actively trading shares of Ocugen over the course of the past ninety days. Most recently, Ramesh Kumar sold 4,500 shares of the business's stock in a transaction on Thursday, October 6th. The shares were sold at an average price of $1.83, for a transaction totalling $8,235.00. Learn More on Ramesh Kumar's trading history.
Who are Ocugen's active insiders?: Ocugen's insider roster includes Kirsten Castillo (Director), Prabhavathi Fernandes (Director), Uday Kompella (Director), Ramesh Kumar (Director), Shankar Musunuri (CEO), Manish Potti (Director), Sanjay Subramanian (CFO), Vijay Tammara (SVP), and Junge Zhang (Director). Learn More on Ocugen's active insiders.

Ramesh Kumar Insider Trading History at Ocugen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/6/2022	Sell	4,500	$1.83	$8,235.00
7/18/2022	Sell	7,500	$2.57	$19,275.00
4/18/2022	Sell	7,500	$2.83	$21,225.00
1/18/2022	Sell	7,500	$4.07	$30,525.00
7/19/2021	Sell	7,500	$6.40	$48,000.00	7,500
4/19/2021	Sell	7,500	$5.33	$39,975.00	7,500

Ramesh Kumar Buying and Selling Activity at Ocugen

Ocugen Company Overview

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Today's Range

Now: $0.99

$0.95

$1.13

50 Day Range

MA: $1.04

$0.89

$1.30

2 Week Range

Now: $0.99

$0.35

$2.11

Volume

7,792,382 shs

Average Volume

6,152,011 shs

Market Capitalization

$283.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.75